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Targeted Radiopharmaceutical Therapy for Advanced Lung
Cancer
Phase I Trial of Rhenium Re188 P2045, a Somatostatin Analog
Martin J. Edelman, MD,* Gerry Clamon, MD,† Daniel Kahn, MD,‡ Martin Magram, MD,§
John Lister-James, MD,, and Bruce R. Line, MD§¶
Background: Both small cell and non-small cell lung cancer over-
express somatostatin receptors (SSTR). P2045 peptide is an 11-
amino acid somatostatin analog that binds with high affinity to
SSTR and can be labeled with Tc-99m to gauge receptor prevalence
or with Re-188 for 2.1 MeV beta radiotherapy. To evaluate the
safety of this approach, a phase I dose-escalation study of Re-188
P2045 in SSTR-positive lung cancer was performed.
Methods: Patients were required to have stage IIIb or IV or
recurrent non-small cell lung cancer or extensive stage or recurrent
small cell lung cancer, performance status 0 to 1, and normal organ
function. There were no limitations on the number of prior therapies.
Tumor SSTR was detected with Tc-99m P2045. If positive and
projected renal dose of radiation from Re-188 P2045 was less than
20 Gy, treatment with escalating doses of Re-188 P2045 was
instituted. Three doses were evaluated 30 mCi/m2, 60 mCi/m2, and
90 mCi/m2. A single dose of Re-188 P2045 was allowed. Dose-
limiting toxicity was defined as  grade 3 nonhematologic toxicity
or grade 4 hematologic toxicity.
Results: Fifteen patients were enrolled. The median age was 61
years. Fourteen patients had 2 prior chemotherapy regimens. All
were imaged with Tc-99m P2045, eight patients received Re-188
P2045. The most common toxicity was mild lymphopenia. The trial
was halted at the 90 mCi/m2 level when three patients were pro-
jected to have renal radiation doses above 20 Gy. The monoclonal
antibody was not determined, and no responses were seen. Five of
the eight patients (62.5%, 95% CI: 24–91%) had stable disease for
at least 8 weeks, all of whom entered the study with progressive
disease. Median overall survival was 11.5 months.
Conclusions: This trial demonstrated that Re-188 P2045 was well
tolerated. Tc-99m P2045 imaging allows identification of patients
who may benefit from this treatment. Although responses were not
seen, survival for these heavily pretreated patients is interesting and
merits further research.
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(J Thorac Oncol. 2009;4: 1550–1554)
One significant problem with current therapy for ad-vanced lung cancer (in addition to the modest degree of
benefit) is that it is difficult to determine which patients will
benefit from treatment. Therefore, a desirable treatment ap-
proach is to be able to prospectively identify patients who
may benefit from a drug before administration of that agent.
Radiopharmaceuticals are uniquely positioned to accomplish
this goal as there is the potential to identify the target in vivo
and in real time without the need for a biopsy and then to
administer a therapy by simply altering the isotope used.
Radioimmunotherapy using monoclonal antibodies to
target radiotherapy (RT) to specific tissues has been used
successfully in treating some cancers, but currently, no ra-
dioimmunotherapies are approved to treat solid tumors.
Moreover, compared with monoclonal antibodies, peptides
offer a better prospect for solid tumor internally administered
RT. Peptides are smaller than antibodies and may be able to
reach actively growing cells within solid tumors. They have
a short plasma half-life and thus deliver a lower radiation
dose to many normal tissues, such as the bone marrow. Small
synthetic peptides (30 amino acids) that have high affinity
for molecular receptors on tumors and exhibit rapid clearance
from the blood are a particularly attractive class of small
molecules for internally administered RT. This approach has
been evaluated with promising results in differentiated neu-
roendocrine tumors.1
P2045, an 11 amino acid peptide, is an analog of the
peptide contained in technetium Tc 99m depreotide (NeoTect),
which is approved for detection of somatostatin receptor
(SSTR)-expressing pulmonary masses.2 SSTR are commonly
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expressed in both small cell lung cancer (SCLC) and non-small
cell lung cancer (NSCLC).3–5 SSTRs are also expressed on
peritumoral blood vessels in several malignancies, raising the
possibility of vascular targeting.6,7 Radiolabeled with Rhenium
Re 188, P2045 (Figure 1) retains the SSTR affinity of depreotide
but with lower kidney and whole body retention. Rhenium 188
is a beta-emitting isotope with a half-life of 17 hours, maximum
particle energy of 2.1 MeV, and a path length of approximately
5 mm. In studies with nude mice, Rhenium Re 188 P2045
caused almost complete inhibition of SSTR-bearing pancreatic
tumors with no acute damage on histopathologic examination to
any other organ or tissue.8
Two dosimetry studies of radiolabeled P2045 have
been conducted. The first trial was an imaging study in which
P2045 was radiolabeled with Technetium Tc 99m to inves-
tigate uptake of the peptide in lung tumors without exposing
humans to Rhenium Re 188. Ten patients received 10 mCi
with either 53 g (five patients) or 265 g (five patients)
peptide. No adverse events (AEs) were noted, and all in-
trathoracic lung tumors showed uptake of P2045. Dosimetry
data from the Technetium Tc 99m P2045 images allowed
estimates of radiation absorbed dose of Rhenium Re 188
P2045 to the lung tumors and kidneys. These predicted doses
were 17 cGy/mCi (range, 0.7–33.0) to the lung tumors and
7.5 cGy/mCi (range, 6.6–9.7) to the kidneys. A subsequent
phase 1 study evaluated safety, pharmacokinetics, biodistri-
bution, and radiation absorbed dose in seven patients admin-
istered a 20 to 25 mCi dose of Technetium Tc 99m P2045,
followed by a 20 to 30 mCi dose (approximately 15 mCi/m2)
of Rhenium Re 188 P2045 5 to 10 days later. There were no
drug-related serious AEs, and all intrathoracic tumors showed
uptake of the study drug.9
Given the frequent presence of SSTRs in both SCLC
and NSCLC and the results of the prior studies demonstrating
excellent tolerance of therapy, a formal phase I trial was
instituted in patients with advanced lung cancer.
METHODS
Patients were eligible if they had a histologically or
cytologically confirmed diagnosis of stage IIIb (pleural effu-
sion) or IV or recurrent NSCLC, extensive stage, or recurrent
SCLC, had an Eastern Cooperative Oncology Group perfor-
mance status (PS) of 0 to 1 and adequate hematologic, renal,
and hepatic function. Adequate hematologic status was de-
fined as white blood count 3000/mm3, hemoglobin 10
g/dl, and platelets 100,000/mm3 was required. Adequate
hepatic and renal function defined as aspartate aminotrans-
ferase or alanine aminotransferase 2.5 the upper limit of
normal (ULN) or 5 ULN if hepatic metastases were
present, total bilirubin 1.5 ULN, and serum creatinine
1.5 ULN were also required. Any chemotherapy or sur-
gery must have been completed 4 weeks prior, and RT must
have been completed 8 weeks before Tc99m P2045 admin-
istration. Patients with central nervous system metastases
were eligible. Those with symptomatic metastases must have
received therapy (i.e., surgery, XRT, and gamma knife) and
be neurologically stable and not require steroid therapy.
Patient evaluation, treatment, and follow-up is outlined in
Figure 2. Tumor SSTR was detected with Tc-99m P2045. This
was determined by visual evaluation of the scans, and any tumor
uptake beyond that of baseline was considered positive. If
positive and the projected renal dose of radiation from Re-188
P2045 (Table 1) was less than 20 Gy, treatment with escalating
doses of Re-188 P2045 was instituted. Three dose levels were
evaluated 30 mCi/m2, 60 mCi/m2, and 90 mCi/m2. A single
administration of Re-188 P2045 was allowed. Dose-limiting
toxicity was defined as  grade 3 nonhematologic toxicity or
grade 4 hematologic toxicity. Assessments of radiographic re-
sponse were performed using the response evaluation criteria in
solid tumors.10 AEs were graded according to the National
Cancer Institute Common toxicity criteria, version 2. All radio-
logic studies were reviewed centrally for calculation of Re-118
P2045 dose to be administered and for assessment of response
and other endpoints. The trial was approved by the institutional
review boards of the participating institutions.
RESULTS
Fifteen patients were enrolled on the study (Table 2).
There were seven men and eight women entered. The median
age was 61 years. Nine patients were PS 0, and six were PS
1. There were 13 patients with NSCLC and two with SCLC.
Fourteen patients had 2 prior chemotherapy regimens. One
patient had refused standard therapy. All 15 patients were
imaged with Tc-99m P2045, and eight patients received
Re-188 P2045. All these eight patients had previously re-
ceived two or more chemotherapy regimens (range, 2–7). The
reasons for not proceeding to Re-188 P2045 were rapid
disease progression (n  2), nonuptake of Tc 99m P2045
(n  2), or projected renal radiation dose above the protocol-
prescribed 20Gy limit (n  3). All patients treated with
Re-188 P2045 (four at 30 mCi/m2, three at 60 mCi/m2, and
one at 90 mCi/m2) had NSCLC.
The most common toxicity was lymphopenia, which
was generally grade 1 to 2 and self-limited in all cases. One
patient experienced grade 3 lymphopenia. Only one patient
developed symptomatic toxicity. This patient experienced
grade 3 abdominal pain, grade 3 hyponatremia, and sudden
death. Autopsy revealed preexisting coronary artery disease,
and his death was assessed as probably unrelated to the study
agent.
All tumors imaged by Tc-99m had uptake of Re-188.
The trial was halted at the 90 mCi/m2 level when three
patients had projected renal radiation doses above 20 Gy.
Four patients were followed for at least 1 year, and there were
no changes in serum creatinine or other evidence of late renal
FIGURE 1. Structure of Re P2045 peptide.
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toxicity over this period. Additionally, no long-term thyroid
or hematologic toxicity was observed.
There was great variability in the estimated absorbed
radiation doses to tumors (Table 3). The absorbed dose was
calculated for selected target lesions in the eight patients who
received therapeutic doses and normalized for an adminis-
tered doses of 90 and 120 mCi. The median absorbed dose
(normalized to a 90 mCi administered dose) was 13 Gy, with
a range of 2 to 99 Gy.
No responses were seen. However, five of the eight
patients (62.5%, 95% CI: 24–91%), all of whom entered with
progressive disease, had stable disease at 8 weeks. The
median event-free survival was 2.9 months, and the median
overall survival was 11.5 months.
DISCUSSION
Current therapy for advanced lung cancer has unques-
tionable benefits in terms of survival and quality of life.11
However, these benefits to do not accrue to every patient, and
many will experience toxicity without benefit. The term
“targeted therapy” has recently been introduced to signify
agents that are directed at targets specific for tumor cells,
most commonly involving pathways involved in tumor
growth and survival. In lung cancer, the most successful of
these therapies has been the epidermal growth factor receptor
inhibitor erlotinib. However, even with this agent, substantial
numbers of patients are treated without benefit and with
toxicity. A related concept is that of “personalized medicine,”
i.e., treatment using agents directed at a specific patient’s
disease. To some extent, this approach has been realized in
the treatment of breast cancer in which specific aspects of an
individual’s disease (hormone status, Her 2-neu expression)
are used to make treatment decisions. This approach requires
tissue sampling. Such sampling is much easier in breast
cancer (and many other malignancies) where the initial man-
agement is usually surgical and a large volume of tissue is
Eligibility Confirmed
Follow-up Weeks 1-8
18FDG-PET scan of tumor area
Kidney rad <20 Gy AND target lesion shows uptake of 
Technetium Tc P2045
Tumor response CR of PR:  CT and 18FDG-PET 
Scans Week 12 or 13
Tumor response SD, PD, or unknown
CT and 18FDG-PET Scans Week 8
Rhenium Re 188 P2045 administration 
and imaging
Kidney rad ≥ 20 Gy AND/OR no uptake of Technetium Tc 99m 
P2045 seen in target lesion
Evaluate SPECT Technetium Tc 99m P2045 images
Estimate kidney radiation absorbed dose
Technetium Tc 99m P2045 administration and 
imaging
Baseline CT Scan
1 week safety follow-up
Early Death or withdrawal
Long-term serum creatinine and thyroid 
function follow-up every 2 months until death
FIGURE 2. Patient evaluation.
TABLE 1. Dose Escalation Scheme
Cohort Dose Re-P2045 (mCi/m2)
1 30
2 60
3 90
4 120
TABLE 2. Patient Demographics
Characteristic Number
Enrolled 15
Sex: M/F 7/8
Performance status 0/1 9/6
Disease
NSCLC 13
SCLC 2
Prior chemotherapy regimens
0 1
1 0
2 6
3 8
NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.
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available. In lung cancer, only a small percentage of patients
(30% with NSCLC and 1% in SCLC) undergo primary
surgical management, and therefore, there is limited avail-
ability of tissue. Furthermore, even where there is tissue
available, it is likely that considerable time has elapsed since
surgery and the presentation of advanced disease. During this
time period, biologic characteristics of the tumor may change.
Hence, there is a need for therapies that can be targeted at
specific abnormalities of the disease at the time of therapy.
Radiopharmaceuticals are uniquely positioned to allow this as
it is possible through alteration in either dose or isotope used
to determine the presence of a target and then to follow
shortly thereafter with treatment directed at the target.
This trial has demonstrated that targeting SSTRs using
this approach is feasible. Eight of 15 enrolled patients were
able to receive therapy. Only two patients did not demon-
strate the presence of SSTR overexpression on the lung
tumors based on imaging with Tc-99m P2045. Actual patient
toxicity was minimal and a single dose of Re 188-P2045 may
have resulted in patient benefit in the form of stable disease
in several patients with heavily pretreated disease. The small
number of patients treated on this study limits any conclu-
sions regarding the efficacy of this agent. Larger studies will
need to be performed to evaluate the potential therapeutic
value of this approach.
The major question confronting future development of
this agent is whether limiting further dose escalation based on
potential renal toxicity is appropriate and if this potential
toxicity can be prevented. The kidney is a late responding
organ to radiation without known early indicators of irrevers-
TABLE 3. Lung Tumor Absorbed Radiation Dose Estimates
Dose
Cohort
mCi/m2
Patient
Number Histology
Smoking
History?
Therapy
Before P2045
Post P2045
Therapy
Target
Lesion
ID
Radiation
Absorbed
Dose (rad)
Dose/mCi/m2/g
rad m2/mCi g
Dose/90
mCi/m2
Gy
Dose/120
mCi/m2
Gy
30 1 Large cell Y CBDCA/pac;
gefitinib
None 1 784 6.2 23.5 31.4
3 1964 37.0 58.9 78.6
4 468 1.7 14 18.7
5 267 0.8 8.0 10.7
2 Squamous Y CBDCA/pac/
XRT
Erlotinib,
BPU
1 58 0.0 1.7 2.3
3 Adenocarcinoma Y CBDCA/pac/
XRT; doc
1 279 1.1 8.4 11.2
4 Squamous Y CBDCA/pac/
XRT
Doc 1 293 1.5 8.8 11.7
2 811 7.5 24.3 32.4
3 1253 23.6 37.6 50.1
4 195 0.3 5.9 7.8
5 631 2.9 18.9 25.2
60 5 Squamous Y CBDCA/pac/
XRT; doc;
gefitinib;
CBDCA/
UCN-01
Gem; sorafenib 1 557 0.1 8.4 11.1
6 Adenocarcinoma N Gem/CBDCA;
WBRT;
gefitinitb; doc
None 1 208 0.0 3.1 4.2
7 Adenocarcinoma Y XRT; gem/
CBDCA/
bex; doc
Erlotinib 1 656 0.4 9.8 13.1
2 883 1.2 13.2 17.7
3 6611 76.7 99.2 132
5 4636 67.2 69.5 92.7
90 8 Adenocarcinoma Y CBDCA/pac/
XRT
Pemetrexed 2 1253 3.3 12.5 16.7
3 1653 16 16.5 22
Highest 6611 77 99 132
Lowest 58 0 2 2
Range 60–6600 0–80 2–99 2–132
Mean 1235 13 23 31
Median 656 2 13 18
Combinations are indicated by “/,” separate therapies are indicated by “;.”
XRT, radiotherapy; WBRT, whole brain radiotherapy; CBDCA, carboplatin; Pac, paclitaxel; Doc, docetaxel; Gem, gemcitabine; UCN-01, 7-OH Staurosporine; Bex, bexarotene;
BPU, benzoylphenylurea.
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ible tissue radiation damage. This lack of an early indicator
for potential irreversible kidney damage poses a challenge for
a dose escalation trial, because it is practically impossible to
follow the conventional approach of titrating the dose upward
to the onset of manageable renal toxicity. A typical approach
to reduce or eliminate the potential for developing renal
failure 6 months or later from administration of Rhenium Re
188 P2045 is to stay below a “cut-off value,” which is
regarded as a value with an acceptable risk of kidney toxicity.
This is commonly accepted to be the “TD5/5” dose value for
the organ of concern (TD5/5 represents the dose in Gy which
poses a 5% risk for the patient to develop radiation caused
toxicity within a 5-year period based on 2 Gy fractionated
external beam radiation therapy). It is questionable whether
this parameter is appropriate for patients with this diagnosis.
The prognosis for advanced refractory lung cancer is exceed-
ingly poor, with a median survival of less than 8 to 12 months
and 20% or fewer patients alive at 2 years and 5 year survival
of 5%. This concern would be more significant if this
approach were validated and used in lower stage disease. If
this issue becomes of concern, others have demonstrated that
the use of amino acid infusions has the potential to reduce or
prevent renal toxicity when similar agents are used.12
CONCLUSIONS
Targeted RT is a novel approach to the problem of
cancer therapy and uniquely offers the ability to confirm the
presence of a molecular target before treatment. This study
has demonstrated that such an approach using Re-188 P2045
is feasible. The survival data for the patients entered on this
study is interesting, but the number is small and much larger
trials will be needed to assess the true impact of this ap-
proach. Furthermore, the true maximum tolerated dose, based
on actual patient toxicity rather than hypothetical toxicity
needs to be established. In addition, the question of whether
this agent can be readministered remains to be established.
Further exploration of Re-188 P2045 in this patient popula-
tion is warranted.
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